Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel
NYSEAMERICAN:AIM

AIM ImmunoTech Q3 2025 Earnings Report

AIM ImmunoTech logo
$0.31 -0.04 (-12.18%)
Closing price 06/26/2026 04:10 PM Eastern
Extended Trading
$0.31 0.00 (-0.03%)
As of 06/26/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

AIM ImmunoTech EPS Results

Actual EPS
-$1.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

AIM ImmunoTech Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AIM ImmunoTech Announcement Details

Quarter
Q3 2025
Date
11/17/2025
Time
Before Market Opens
Conference Call Date
Monday, November 17, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

AIM ImmunoTech's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

AIM ImmunoTech Earnings Headlines

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316820/29489/en/aim-immunotech-accelerates-toward-potential-pivotal-pancreatic-cancer-program-as-ampligen-continues-to-advance-through-key-clinical-milestones.html
AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences
June 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260623153580/en/aim-sports-group%e2%80%99s-national-socal-cup-%e2%80%98the-showcase%e2%80%99-event-serves-up-a-weekend-of-new-experiences/
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
June 28 at 1:00 AM  |  Profits Run (Ad)
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315298/29489/en/aim-immunotech-to-present-in-the-webull-corporate-connect-webinar-series.html
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/18/3314251/29489/en/aim-immunotech-achieves-clinical-milestone-as-final-subject-receives-first-dose-in-phase-2-duripanc-study-in-metastatic-pancreatic-cancer.html
AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313210/0/en/aim-talks-china-2026-convenes-in-guangzhou-advancing-strategic-partnerships-and-cross-border-investment-across-the-greater-bay-area.html
See More AIM ImmunoTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AIM ImmunoTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AIM ImmunoTech and other key companies, straight to your email.

About AIM ImmunoTech

AIM ImmunoTech (NYSEAMERICAN:AIM) is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways.

Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market.

View AIM ImmunoTech Profile
Earnings Tools